BioSpace News Archive

Astellas’ zolbetuximab hit the mark in a second late-stage trial in Claudin-18.2-positive gastric cancer.

Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.

Covalent biologic company Enlaza launches with $61M in seed financing.

Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.

Henry Schein, Inc. today announced a definitive agreement with the shareholders of Biotech Dental S.A.S.

Alvotech announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds, convertible into new fully paid ordinary shares of Alvotech.

Evelo Biosciences, Inc. today announced it has entered into a senior secured loan agreement with Horizon Technology Finance Corporation (Horizon) (Nasdaq: HRZN).

Diffusion Pharmaceuticals Inc. today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd.

Ocugen, Inc. today announced that the U.S. Food & Drug Administration (FDA) agreed to Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart ®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.

Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT Genomics Holdings Company Limited (“ACT”), an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the UK.